Tags

Type your tag names separated by a space and hit enter

Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
Neurodegener Dis Manag. 2018 04; 8(2):105-113.ND

Abstract

AIM

Complaints about Δ9-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex®; GW Pharma Ltd, Salisbury, UK) in the management of multiple sclerosis spasticity include unpleasant taste and oral mucosal anomalies. This pilot study assessed the use of sugar-free chewing gum and/or a refrigerated bottle of THC:CBD oromucosal spray to mitigate these effects.

MATERIALS & METHODS

Patients with multiple sclerosis spasticity (n = 52) at six sites in Italy who were receiving THC:CBD oromucosal spray and had associated oral mucosal effects were randomized into Group A (chewing gum; n = 15); Group B (cold bottle; n = 20); and Group C (cold bottle + chewing gum; n = 17).

RESULTS

Taste perception in patients receiving chewing gum ± cold bottle intervention (Groups A and C combined) was significantly (p = 0.0001) improved from baseline to week 4 while maintaining spasticity control.

CONCLUSION

Patient comfort, satisfaction and treatment adherence may benefit from these interventions.

Authors+Show Affiliations

Multiple Sclerosis Center, II Division of Neurology, Department of Clinical & Experimental Medicine, Second University of Naples, Naples, Italy.Department of Neurology, University of Eastern Piedmont, Novara, Italy.Neurological Clinic, Department of Experimental & Clinical Medicine, Marche Polytechnic University, Ancona, Italy.Neurology Service, Ospedale A. di Summa Perrino, Brindisi, Italy.Dipartimento di Medicina, Clinica Neurologica, Università degli Studi di Perugia, Perugia, Italy.Azienda Ospedaliera, Ospedale S. Corona, Pietra Ligure, Italy.Multiple Sclerosis Center, II Division of Neurology, Department of Clinical & Experimental Medicine, Second University of Naples, Naples, Italy.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29683408

Citation

Lus, Giacomo, et al. "Palatability and Oral Cavity Tolerability of THC:CBD Oromucosal Spray and Possible Improvement Measures in Multiple Sclerosis Patients With Resistant Spasticity: a Pilot Study." Neurodegenerative Disease Management, vol. 8, no. 2, 2018, pp. 105-113.
Lus G, Cantello R, Danni MC, et al. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study. Neurodegener Dis Manag. 2018;8(2):105-113.
Lus, G., Cantello, R., Danni, M. C., Rini, A., Sarchielli, P., Tassinari, T., & Signoriello, E. (2018). Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study. Neurodegenerative Disease Management, 8(2), 105-113. https://doi.org/10.2217/nmt-2017-0056
Lus G, et al. Palatability and Oral Cavity Tolerability of THC:CBD Oromucosal Spray and Possible Improvement Measures in Multiple Sclerosis Patients With Resistant Spasticity: a Pilot Study. Neurodegener Dis Manag. 2018;8(2):105-113. PubMed PMID: 29683408.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study. AU - Lus,Giacomo, AU - Cantello,Roberto, AU - Danni,Maura Chiara, AU - Rini,Agusto, AU - Sarchielli,Paola, AU - Tassinari,Tiziana, AU - Signoriello,Elisabetta, Y1 - 2018/04/23/ PY - 2018/4/24/pubmed PY - 2019/1/3/medline PY - 2018/4/24/entrez KW - Sativex KW - THC:CBD KW - multiple sclerosis KW - oral cavity complaints KW - oromucosal spray KW - spasticity KW - taste perception SP - 105 EP - 113 JF - Neurodegenerative disease management JO - Neurodegener Dis Manag VL - 8 IS - 2 N2 - AIM: Complaints about Δ9-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex®; GW Pharma Ltd, Salisbury, UK) in the management of multiple sclerosis spasticity include unpleasant taste and oral mucosal anomalies. This pilot study assessed the use of sugar-free chewing gum and/or a refrigerated bottle of THC:CBD oromucosal spray to mitigate these effects. MATERIALS & METHODS: Patients with multiple sclerosis spasticity (n = 52) at six sites in Italy who were receiving THC:CBD oromucosal spray and had associated oral mucosal effects were randomized into Group A (chewing gum; n = 15); Group B (cold bottle; n = 20); and Group C (cold bottle + chewing gum; n = 17). RESULTS: Taste perception in patients receiving chewing gum ± cold bottle intervention (Groups A and C combined) was significantly (p = 0.0001) improved from baseline to week 4 while maintaining spasticity control. CONCLUSION: Patient comfort, satisfaction and treatment adherence may benefit from these interventions. SN - 1758-2032 UR - https://www.unboundmedicine.com/medline/citation/29683408/Palatability_and_oral_cavity_tolerability_of_THC:CBD_oromucosal_spray_and_possible_improvement_measures_in_multiple_sclerosis_patients_with_resistant_spasticity:_a_pilot_study_ L2 - http://www.futuremedicine.com/doi/full/10.2217/nmt-2017-0056?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -